Success Rate of Radioactive Iodine Therapy in Graves’ Disease Using Dose Corrected for Thyroid Gland Size

Main Article Content

Peerapon Kiatkittikul
https://orcid.org/0000-0001-7076-3829
Yutapong Raruenrom
https://orcid.org/0000-0002-2384-0649
Daris Theerakulpisut
https://orcid.org/0000-0002-1338-511X
Charoonsak Somboonporn
https://orcid.org/0000-0002-3922-1375

Abstract

Objective: Dose corrected for thyroid gland size is one of the methods used to determine I-131 activity for patients with Graves’ disease. This study was aimed to find the success rate of this method and the predictors for successful I-131 treatment.
Methods: This retrospective descriptive study was conducted in patients with Graves’ disease who received the first dose of radioactive iodine (RAI) therapy. Patients received a fixed RAI dose of either 10, 15, 20, 25, or 30 mCi for corresponding thyroid gland size of ≤ 50, 51-100, 101-150, 151-200, and >200 grams, respectively. The treatment outcome was assessed 6 to 9 months after the therapy based on serum free thyroxine and serum thyroid stimulating hormone. Successful treatment was defined as euthyroid and hypothyroid.
Results: A total of 179 patients (126 females; mean age: 40.8 years) were enrolled. One patient was excluded from the outcome analysis due to undetermined laboratory results. The success rate of RAI therapy was 50% (95% CI: 42.4-57.6). Patients with gland size ≤ 50 gm had the highest success rate of 59.6%. Multivariable analysis showed no significant association between sex, thyroid gland size, and prior antithyroid drug use and successful treatment.
Conclusion: First RAI therapy using dose corrected for thyroid gland size had a modest success rate of 50% in patients with Grave’s disease. Sex, thyroid gland size, and prior antithyroid drug use were not significantly associated with the treatment outcome.

Downloads

Download data is not yet available.

Article Details

How to Cite
Kiatkittikul, P., Raruenrom, Y., Theerakulpisut, D., & Somboonporn, C. (2021). Success Rate of Radioactive Iodine Therapy in Graves’ Disease Using Dose Corrected for Thyroid Gland Size : . Siriraj Medical Journal, 73(2), 108–113. https://doi.org/10.33192/Smj.2021.15
Section
Original Article

References

1. Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. Eur Thyroid J 2018;7:167–86.

2. Smith TJ, Hegedüs L. Graves’ Disease. N Engl J Med 2016;375:1552–65.

3. Burch HB, Cooper DS. Management of Graves Disease: A Review. JAMA 2015;314:2544–54.

4. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid 2016;26:1343–421.

5. Nayak B, Burman K. Thyrotoxicosis and thyroid storm. Endocrinol Metab Clin North Am 2006;35:663–86.

6. Bartalena L. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol 2013;9:724–34.

7. Stokkel MPM, Handkiewicz Junak D, Lassmann M, Dietlein M, Luster M. EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging 2010;37:2218–28.

8. Silberstein EB, Alavi A, Balon HR, Clarke SEM, Divgi C, Gelfand MJ, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med 2012 ;53:1633–51.

9. de Rooij A, Vandenbroucke JP, Smit JWA, Stokkel MPM, Dekkers OM. Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis. Eur J Endocrinol 2009;161:771–7.

10. Canto AU, Dominguez PN, Jimeno CA, Obaldo JM, Ogbac RV. Comparison of Fixed versus Calculated Activity of Radioiodine for the Treatment of Graves Disease in Adults. Endocrinol Metab (Seoul) 2016;31:168–73.

11. Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves’ hyperthyroidism. J Clin Endocrinol Metab 2003 ;88:978–83.

12. Kalinyak JE, McDougall IR. How should the dose of iodine-131 be determined in the treatment of Graves’ hyperthyroidism? J Clin Endocrinol Metab 2003;88:975–7.

13. Bonnema SJ, Hegedüs L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev 2012;33:920–80.

14. Santos RB, Romaldini JH, Ward LS. A randomized controlled trial to evaluate the effectiveness of 2 regimens of fixed iodine (131I) doses for Graves disease treatment. Clin Nucl Med 2012;37:241–4.

15. Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab 2001 ;86:3611–7.

16. El-Kareem MA, Derwish WA, Moustafa HM. Response rate and factors affecting the outcome of a fixed dose of RAI-131 therapy in Graves’ disease: a 10-year Egyptian experience. Nucl Med Commun 2014;35:900–7.

17. Moura-Neto A, Mosci C, Santos AO, Amorim BJ, de Lima MCL, Etchebehere ECSC, et al. Predictive factors of failure in a fixed 15 mCi 131I-iodide therapy for Graves’ disease. Clin Nucl Med 2012;37:550–4.

18. Fanning E, Inder WJ, Mackenzie E. Radioiodine treatment for graves’ disease: a 10-year Australian cohort study. BMC Endocr Disord 2018;18:94.

19. Tannahill AJ, Hooper MJ, England M, Ferriss JB, Wilson GM. Measurement of thyroid size by ultrasound, palpation and scintiscan. Clin Endocrinol (Oxf) 1978;8:483–6.

20. Thamcharoenvipas S, Kerr SJ, Tepmongkol S. Finding the best effective way of treatment for rapid I-131 turnover Graves’ disease patients: A randomized clinical trial. Medicine (Baltimore) 2019;98:e15573.

21. Meller B, Haase A, Seyfarth M, Wenzel BE, Richter E, Baehre M. [Reduced radioiodine uptake at increased iodine intake and 131I-induced release of “cold” iodine stored in the thyroid]. Nuklearmedizin 2005;44:137–42.

22. Santarosa VA, Orlandi DM, Fiorin LB, Kasamatsu TS, Furuzawa GK, Kunii IS, et al. Low iodine diet does not improve the efficacy of radioiodine for the treatment of Graves’ disease. Arch Endocrinol Metab 2015;59:501–6.

23. Bonnema SJ, Bennedbaek FN, Veje A, Marving J, Hegedüs L. Propylthiouracil before 131I therapy of hyperthyroid diseases: effect on cure rate evaluated by a randomized clinical trial. J Clin Endocrinol Metab 2004;89:4439–44.

24. Pirnat E, Zaletel K, Gaberšček S, Hojker S. The outcome of 131I treatment in Graves’ patients pretreated or not with methimazole. Hell J Nucl Med 2011;14:25–9.